In recent years, more and more therapies have hit the market for the treatment of patients with inflammatory bowel disease (IBD).
Biologics are revolutionizing treatment in this regard and are expected to receive more than approval from the US Food and Drug Administration (FDA) in the next few years.
However, there are still areas of care that need improvement.
Access remains a problem, especially in rural areas and minority communities.
Another opportunity for growth is to collaborate with specialists other than gastrointestinal medicine and expand the range of medical care.
in an interview with HCP Live® Between 2023 Crohn’s Disease and Colitis Conference In Denver, Laura Wingate, executive vice president of education, support and advocacy for the Crohn’s & Colitis Foundation, spoke about the state of IBD care and where it can be improved in the next few years.
Wingate also spoke about the main role of the Crohn’s Disease and Colitis Foundation and what he gains from attending conferences such as the Crohn’s Disease and Colitis Conference.
“Our role is to educate healthcare professionals about all the advances, all the latest treatment options, and all the best practices that are being made to ensure optimal patient care.” As well as weaving in perspectives and patient experiences.”
One area that could lead to some improvements is the use of telemedicine during the COVID-19 pandemic.
“Patients are very receptive to telemedicine,” says Wingate. “While the gerontological community likes telemedicine, there are some concerns, especially when it comes to newly diagnosed people.”